Spots Global Cancer Trial Database for Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Official Title: A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination With Abiraterone in Patients With Metastatic Prostate Cancer
Study ID: NCT05177042
Conditions
Interventions
Study Description
Brief Summary: Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with rising PSA values on abiraterone.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Clinical Trial Site, Santa Monica, California, United States
Clinical Trial Site, New Haven, Connecticut, United States
Clinical Trial Site, Fort Myers, Florida, United States
Clinical Trial Site, Boston, Massachusetts, United States
Clinical Trial Site, Columbus, Ohio, United States
Clinical Trial Site, Portland, Oregon, United States
Clinical Trial Site, Myrtle Beach, South Carolina, United States
Clinical Trial Site, Nashville, Tennessee, United States
Clinical Trial Site, Charlottesville, Virginia, United States
Clinical Trial Site, Vancouver, British Columbia, Canada
Clinical Trial Site, Toronto, Ontario, Canada
Clinical Trial Site, Montreal, Quebec, Canada
Clinical Trial Site, Caen, , France
Clinical Trial Site, Paris, , France
Clinical Trial Site, Villejuif, , France
Clinical Trial Site, London, England, United Kingdom
Clinical Trial Site, Cardiff, Wales, United Kingdom
Clinical Trial Site, Preston, , United Kingdom
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
